Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders [Yahoo! Finance]
Daxor Corporation (DXR)
NASDAQ:AMEX Investor Relations:
daxor.com/investors
Company Research
Source: Yahoo! Finance
measurement technology today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 2, 2026 from CEO & President, Michael Feldschuh. Dear Valued Shareholders, "To measure is to know. If you cannot measure it, you cannot improve it." — Lord Kelvin Lord Kelvin's timeless scientific principle perfectly encapsulates the mission of Daxor Corporation. In medicine, you cannot effectively treat what you cannot accurately measure. Looking back at the entirety of 2025, our commitment to replacing clinical guesswork with precise measurement – changing healthcare outcomes and economics – has culminated in a truly transformative year for Daxor Corporation. Last year marked a crucial inflection point for our company, characterized by groundbreaking product innovation, rapidly expanding market adoption, undeniable clinical validation, and increased visibility for our Blood Volume Analysis (BVA ™ ) technology. Financial and Opera
Show less
Read more
Impact Snapshot
Event Time:
DXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DXR alerts
High impacting Daxor Corporation news events
Weekly update
A roundup of the hottest topics
DXR
News
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to ShareholdersGlobeNewswire
- Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per ShareGlobeNewswire
- Daxor Scales Outpatient Presence; Launches BVA Diagnostic Program in TennesseeGlobeNewswire
- Daxor (NASDAQ:DXR) is now covered by analysts at Lake Street Capital. They set a "buy" rating on the stock.MarketBeat
- Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic BusinessGlobeNewswire
DXR
Sec Filings
- 3/2/26 - Form N-CSR
- 3/2/26 - Form NPORT-P
- 2/9/26 - Form 40-8F-2
- DXR's page on the SEC website